AI assistant
Sending…
Insight Molecular Diagnostics Inc. — Director's Dealing 2018
Aug 16, 2018
34238_dirs_2018-08-16_4f38a4f9-6169-4dea-8af8-efed86434114.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2018-08-06
Reporting Person: Parker Albert P (Chief Operating Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Option to Purchase Common Stock | $2.30 | 2028-08-05 | Common Stock (250000) | Direct |
Footnotes
F1: 200,000 options shall vest in installments based upon the attainment of certain milestones in the development of OncoCyte's lung cancer diagnostic test, DetermaVu, and 50,000 options shall vest upon completion of six months of service as an OncoCyte employee.
More from Insight Molecular Diagnostics Inc.
Annual Report
2026
Apr 30
Regulatory Filings
2026
Apr 30
Regulatory Filings
2026
Feb 26
Director's Dealing
2026
Feb 12
Major Shareholding Notification
2026
Feb 12
Regulatory Filings
2026
Feb 12
Regulatory Filings
2026
Feb 11
Regulatory Filings
2026
Feb 11
Director's Dealing
2025
Nov 13
Interim / Quarterly Report
2025
Nov 10